Want to see HK:1609 full AI Analyst Report?
Star Sports Medicine Co., Ltd Class H (1609) AI Stock Analysis
Star Sports Medicine Co., Ltd Class H
(HKEX:1609)
The score is supported primarily by strong financial performance, including profitable growth, low leverage, and improving cash generation. Weak technical momentum and a relatively high P/E ratio materially reduce the score.
Star Sports Medicine Co., Ltd Class H (1609) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.37B
- Dividend Yield
- ―
- Average Volume (3M)
- 284.24K
- Price to Earnings (P/E)
- 25.1
- Beta (1Y)
- 1.24
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 384
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Star Sports Medicine Co., Ltd Class H Business Overview & Revenue Model
Company Description
Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carbon...
Star Sports Medicine Co., Ltd Class H Financial Statement Overview
Summary
Strong revenue growth, sharply improved profitability, low leverage, expanding equity returns, and rising operating and free cash flow support a high score. Historical losses, slowing growth, debt increases, and variable cash conversion remain moderate risks.
Income Statement
89Very PositiveBalance Sheet
87Very PositiveCash Flow
83Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 397.82M | 402.75M | 327.12M | 238.54M | 146.60M | 89.58M |
| Gross Profit | 295.86M | 298.62M | 227.59M | 177.31M | 103.94M | 59.68M |
| EBITDA | 176.29M | 169.36M | 121.86M | 77.68M | 48.33M | -137.49M |
| Net Income | 146.98M | 136.97M | 95.39M | 57.11M | 40.34M | -135.26M |
Balance Sheet | ||||||
| Total Assets | 1.43B | 764.08M | 617.33M | 451.28M | 346.92M | 347.22M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12B | 539.78M | 434.06M | 356.37M | 272.84M | 263.70M |
| Total Debt | 31.15M | 32.62M | 22.58M | 8.33M | 11.06M | 12.46M |
| Total Liabilities | 154.66M | 154.66M | 146.09M | 76.51M | 18.69M | 60.58M |
| Stockholders Equity | 1.30B | 609.42M | 471.24M | 374.77M | 328.24M | 286.63M |
Cash Flow | ||||||
| Free Cash Flow | 195.02M | 122.88M | 67.36M | 58.60M | 47.30M | 5.96M |
| Operating Cash Flow | 207.50M | 157.12M | 94.52M | 79.86M | 55.81M | 9.82M |
| Investing Cash Flow | -319.03M | -120.56M | -371.25M | -21.17M | 6.03M | 1.54M |
| Financing Cash Flow | -16.72M | -9.35M | 10.13M | 24.59M | 133.36M | 58.27M |
Star Sports Medicine Co., Ltd Class H Peers Comparison
Overall Rating
- HK:160974.1Outperform
HK:033172Outperform
HK:862961Neutral
HK:392849Neutral
HK:226242Neutral
HK:992931Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1609 | 74Outperform | HKD 2.80B | 25.11 | 13.02% | ― | ― | ― |
| HK:0331 | 72Outperform | HKD 2.40B | 5.86 | 28.73% | 7.02% | -2.76% | -7.88% |
| HK:8629 | 61Neutral | HKD 247.68M | 9.57 | 11.30% | 2.88% | 86.04% | 118.12% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:3928 | 49Neutral | HKD 14.14B | -326.89 | -19.61% | ― | -25.67% | -1034.21% |
| HK:2262 | 42Neutral | HKD 370.96M | 31.25 | 3.68% | ― | 4.28% | 25.30% |
| HK:9929 | 31Underperform | HKD 2.40B | -33.01 | -42.47% | ― | 33.88% | -735.09% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1609 | Star Sports Medicine Co., Ltd Class H | 51.00 | -164.00 | -76.28% | |
| HK:9929 | SEM Holdings Limited | 1.20 | 1.12 | 1400.00% | |
| HK:2262 | Steve Leung Design Group Limited | 0.33 | -0.78 | -70.45% | |
| HK:0331 | FSE Lifestyle Services Limited | 5.33 | -0.12 | -2.11% | |
| HK:3928 | S&T Holdings Ltd. | 28.50 | 23.26 | 443.89% | |
| HK:8629 | Guangdong Syntrust GK Testing and Certification Tech Service Center Co., Ltd. Class H | 7.30 | 0.44 | 6.37% |
Star Sports Medicine Co., Ltd Class H Corporate Events
Star Sports Medicine Calls EGM to Approve 2026 Share Incentive Scheme
Star Sports Medicine Co., Ltd. has called a second extraordinary shareholders’ meeting for October 22, 2026, in Beijing, open to eligible H-shareholders recorded on the register by the specified cut-off date. Shareholders may vote in person or...
Star Sports Medicine Wins EU MDR and Overseas Device Approvals
Star Sports Medicine Co., Ltd is a China-based sports medicine manufacturer focused on medical devices and surgical instruments for joint repair and arthroscopic procedures. Its portfolio spans implants, active devices, consumables and endoscopic ins...
Star Sports Medicine Launches Authorized H-Share Buyback Plan
Star Sports Medicine Co., Ltd. has received shareholder approval at its 2025 annual meeting for a general mandate allowing the board to repurchase up to 10% of its issued H shares, with an initial plan to buy back up to about 2.90 million shares, or...
Star Sports Medicine Boosts Revenue but Sees Interim Profit Decline on Higher Costs
Star Sports Medicine Co., Ltd reported a 21.6% year-on-year increase in revenue to RMB163.4 million for the six months ended 30 June 2026, driven by strong gross profit growth of 21.8% to RMB121.3 million, underscoring solid topline momentum in its s...
Star Sports Medicine Sets Board Meeting to Approve Interim Results and Consider Dividend
Star Sports Medicine Co., Ltd. has called a board meeting for August 17, 2026, to review and approve its interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to recommend the...
Star Sports Medicine unveils 2026 share incentive scheme to align talent and investors
Star Sports Medicine Co., Ltd. plans to adopt a 2026 share incentive scheme, subject to shareholder approval at an upcoming meeting, to strengthen its long-term incentive mechanisms. The scheme uses a trust structure to acquire H shares from the mark...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026